Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: Dysregulated enteroadipocyte axis as a novel feature of fatty liver

American Journal of Clinical Nutrition

Volumn 89, Issue 2, 2009, Pages 558-567

  Musso, Giovanni ^a   Gambino, Roberto ^b   Pacini, Giovanni ^c   De Michieli, Franco ^b   Cassader, Maurizio ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIOXIDANT; CYTOKERATIN 18; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INCRETIN; LIPOPROTEIN; POLYUNSATURATED FATTY ACID; RESISTIN; SATURATED FATTY ACID; TRANSCRIPTION FACTOR 7 LIKE 2;

ADIPOCYTE; ADULT; AGE DISTRIBUTION; ALCOHOL LIVER CIRRHOSIS; APOPTOSIS; ARTICLE; BODY FAT; BODY MASS; CELL METABOLISM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROL GROUP; CONTROLLED STUDY; DISEASE ASSOCIATION; FAT INTAKE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; LIPID DIET; LIPID METABOLISM; LIVER INJURY; MALE; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL;

ADIPOKINES; ADULT; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIET RECORDS; DIETARY FATS; FATTY ACIDS, VOLATILE; FATTY LIVER; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; KERATIN-18; LIPID METABOLISM; MALE; POLYMORPHISM, GENETIC; POSTPRANDIAL PERIOD; RESISTIN; TCF TRANSCRIPTION FACTORS;

EID: 59649114145     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2008.26720     Document Type: Article

References (49)

1. Yan E, Durazo F, Tong M, Hong K. Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. Nutr Rev 2007;65:376-84.
2. Sattar N, McConnachie A, Ford I, et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007;56:984-91.
3. Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ. Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int 2006;26:1015-7.
4. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 2007;282:34139-47.
5. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007;117:143-52.
6. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007;50:1752-62.
7. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance and associated metabolic disturbances induced in mice by prolonged consumption of high fat diet. Am J Physiol Endocrinol Metab 2007;293:E1746-55.
8. Song DH, Getty-Haushik L, Tseng E, Simon J, Corkey B, Wolfe MM. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastro-enterology 2007;133:1796-805.
9. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 2006;55(suppl 2):S86-91.
10. Thomsen C, Rasmussen O, Lousen T, et al. Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 1999;69:1135-43.
11. Arsov T, Carter CZ, Nolan CJ, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006;342:1152-9.
12. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005;90:2804-9.
13. Robertson RP, Harmon J, Tran POT, Poitout V. β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004;53(suppl):S119-24.
14. Harding AH, Day NE, Khaw KT, et al. Dietary fat and the risk of clinical type 2 diabetes: the European prospective investigation of Cancer-Norfolk study. Am J Epidemiol 2004;159:73-82.
15. Damcott CM, Pollin TI, Reinhart LJ, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006;55:2654-9.
16. Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M. Transcription Factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology (Epub ahead of print 26 Sept 2008).
17. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes. Cause or consequence of the diabetic state? Diabetes 2007;56:1951-9.
18. Niswender KD, Magnuson MA. Obesity and the β cell: lessons from leptin. J Clin Invest 2007;117:2753-6.
19. Ravikumar B, Carey PE, Snaar JE, et al. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes. Am J Physiol Endocrinol Metab 2005;288:E789-97.
20. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
21. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
22. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict non-alcoholic fatty liver disease. Clin Chem 2007;53:686-92.
23. Pisani P, Faggiano F, Krogh V, Palli D, Vineis P, Berrino F. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. Int J Epidemiol 1997;26(suppl 1): S152-60
24. Carnovale E. Marletta. Food composition table. Istituto Nazionale della Nutrizione. Milano: EDRA, 1997.
25. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16.
26. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH. Hepatology 2008;47:1167-77.
27. On YK, Park R, Hyon MS, Kim SK, Kwon YJ. Are low total serum antioxidant status and elevated levels of C-reactive protein and monocyte chemotactic protein-1 associated with cardiac syndrome X? Circ J 2005;69:1212-7.
28. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hep- atology 2006;44:27-33.
29. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from non-alcoholic steatohepatitis. World J Gastroenterol 2007;13:837-44.
30. Yagmur E, Trautwein C, Leers MPG, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK 18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem 2007;40:651-5.
31. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001;24:539-48.
32. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003;17:305-22.
33. Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab 2001;28:E966-74.
34. Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract 2006;72:298-301.
35. Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004;150:97-104.
36. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care 2007;30:1544-8.
37. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.
38. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678-87.
39. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001;50: 2497-504.
40. Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide: evidence and clinical opportunity for development of new obesity-diabetes drugs? Diabetes Vasc Dis Res 2007;4:151-3.
41. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008;57:190-8.
42. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signalling prevents obesity. Nat Med 2002;8:738-42.
43. Gniuli D, Dalla Libera L, Caristo ME, Calvani R, Castagneto M, Mingrone G. High saturated-fat diet induces apoptosis in rat enterocytes and blunts GIP and insulin-secretive responses to oral glucose load. Int J Obes (Lond) 2008;32:871-4.
44. Paniagua JA, Gallego de la Sacristana A, Vidal-Puig A, et al. Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 2007;30:1717-23.
45. Nagao K, Inoue N, Wang YM, Shirouchi B, Yanagita T. Dietary conjugated linoleic acid alleviates nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Nutr 2005;135:9-13.
46. Ide T. Interaction of fish oil and conjugated linoleic acid in affecting hepatic activity of lipogenic enzymes and gene expression in liver and adipose tissue. Diabetes 2005;54:412-23.
47. Malhi H, Bronk SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006;281:12093-101.
48. Boden G, She P, Mozzoli M, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-κB pathway in rat liver. Diabetes 2005;54:3458-65.
49. Puri P, Mirshahi F, Cheung O, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008;134:568-76.